IPH4502 在晚期实体瘤患者中的安全性和耐受性
IPH4502 作为单药治疗晚期实体瘤的安全性、耐受性和有效性的第一阶段、开放标签、多中心研究
This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are known to express Nectin-4
研究概览
详细说明
This is a first-in-human, open-label, multicenter, single-arm Phase 1 study, with a part 1 dose escalation guided by a Bayesian optimal interval design with backfilling (BOIN-BF), followed by a part 2 dose optimization in up to 2 selected indications. This study is to measure the safety, tolerability, pharmacokinetics, and preliminary efficacy of escalating doses of IPH4502 in patients with advanced solid tumors that are known to express Nectin-4.
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
-
Lyon、法国、69008
- Centre Léon Bérard
-
Villejuif、法国、94805
- Gustave Roussy Cancer Institute
-
-
-
-
Massachusetts
-
Boston、Massachusetts、美国、02114
- Massachusetts General Hospital - Boston
-
-
New Jersey
-
Hackensack、New Jersey、美国、07601
- John Theurer Cancer Center
-
-
New York
-
New York、New York、美国、10029
- Mount Sinai Tisch Cancer Center
-
-
Texas
-
Dallas、Texas、美国、75039
- NEXT Oncology - Dallas
-
-
Virginia
-
Fairfax、Virginia、美国、22031
- NEXT Oncology - Virginia
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Main Inclusion Criteria:
- Histologically confirmed, unresectable, locally advanced or metastatic solid tumors that are known to express Nectin-4
- Prior systemic treatment for locally advanced or metastatic disease, yet no therapy with demonstrated clinical benefit for the tumor type is available.
- Measurable disease according to RECIST 1.1.
- Archival tumor tissue obtained within 4 months of screening and since the last anticancer therapy prior to the study or agree to undergo a tumor biopsy at baseline.
- Adequate organ function and hematological function.
Main Exclusion Criteria:
- Known or suspected brain metastases.
- Participants with an active infection, Any other infection requiring systemic treatment or latent infection.
- Participants with clinically significant comorbidity(s).
- History of treatment for, or suspicion or confirmed interstitial lung disease (ILD) at baseline.
- Condition being treated with systemic corticosteroids or immunosuppressive therapy during IPH4502 treatment.
- Thromboembolic event requiring anticoagulation therapy ≤14 days prior to the first dose of IPH4502.
- Clinically significant cardiovascular disease and/or cardiac repolarization abnormality.
- Participants with symptomatic heart failure, Acute coronary syndromes
- Participant is receiving or has received anticancer therapy prior to enrolment that may have impact on the assessment of IPH4502.
- Major surgery ≤28 days and minor surgery ≤7 days prior to first dose of IPH4502 or 6 months for coronary artery bypass surgery.
- Concomitant medications or vaccines : Live-attenuated vaccines ≤ 6 weeks prior to first dose of IPH4502; systemic corticosteroids or other immunosuppressive agents within 14 days prior to the first dose of IPH4502; systemic use of moderate or strong CYP 3A4 inhibitors; systemic use of moderate or strong CYP 3A4 inducers.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:IPH4502单一疗法
|
Part 1 (dose escalation) and Part 2 (dose optimization) |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Safety and Tolerability
大体时间:From time of first dose through treatment period, including the follow-up: up to 24 months
|
To evaluate the incidence of AEs, SAEs, TEAEs, and DLTs. |
From time of first dose through treatment period, including the follow-up: up to 24 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Maximum Observed Plasma Concentration (Cmax)
大体时间:From time of informed consent through treatment period, including the follow-up: up to 24 months
|
To characterize and evaluate the pharmacokinetic profile of IPH4502. |
From time of informed consent through treatment period, including the follow-up: up to 24 months
|
|
Area Under the Plasma Concentration (AUC)
大体时间:From time of informed consent through treatment period, including the follow-up: up to 24 months
|
To characterize and evaluate the pharmacokinetic profile of IPH4502. |
From time of informed consent through treatment period, including the follow-up: up to 24 months
|
|
Incidence of antidrug antibodies (ADA) against IPH4502
大体时间:From time of informed consent through treatment period, including the follow-up: up to 24 months
|
To evaluate the immunogenicity of IPH4502. |
From time of informed consent through treatment period, including the follow-up: up to 24 months
|
|
Objective Response Rate (ORR)
大体时间:From time of informed consent through treatment period, including the follow-up: up to 24 months
|
To investigate any preliminary antitumor activity of IPH4502. |
From time of informed consent through treatment period, including the follow-up: up to 24 months
|
|
Duration Of Response (DoR)
大体时间:From time of informed consent through treatment period, including the follow-up: up to 24 months
|
To investigate any preliminary antitumor activity of IPH4502. |
From time of informed consent through treatment period, including the follow-up: up to 24 months
|
|
Progression Free Survival (PFS)
大体时间:From time of informed consent through treatment period, including the follow-up: up to 24 months
|
To investigate any preliminary antitumor activity of IPH4502. |
From time of informed consent through treatment period, including the follow-up: up to 24 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
- 泌尿生殖系统疾病
- 生殖器疾病
- 内分泌系统疾病
- 生殖器肿瘤,男性
- 泌尿生殖系统肿瘤
- 按部位分类的肿瘤
- 肿瘤
- 生殖器疾病,男性
- 前列腺疾病
- 男性泌尿生殖系统疾病
- 女性泌尿生殖系统疾病
- 女性泌尿生殖系统疾病和妊娠并发症
- 肠道疾病
- 呼吸道疾病
- 组织学类型的肿瘤
- 消化道肿瘤
- 消化系统肿瘤
- 消化系统疾病
- 肠胃疾病
- 胃病
- 肠道肿瘤
- 直肠疾病
- 子宫疾病
- 生殖器疾病,女性
- 肺部疾病
- 内分泌腺肿瘤
- 头颈肿瘤
- 肿瘤、腺体和上皮
- 呼吸道肿瘤
- 胸部肿瘤
- 结肠疾病
- 食道疾病
- 肺肿瘤
- 卵巢疾病
- 附件疾病
- 生殖器肿瘤,女性
- 性腺疾病
- 皮肤病
- 乳腺疾病
- 癌
- 肿瘤,鳞状细胞
- 宫颈疾病
- 神经外胚层肿瘤
- 肿瘤、生殖细胞和胚胎
- 肿瘤,神经组织
- 癌,支气管癌
- 支气管肿瘤
- 子宫肿瘤
- 神经内分泌肿瘤
- 痣和黑色素瘤
- 皮肤肿瘤
- 癌,鳞状细胞
- 食道肿瘤
- 乳腺肿瘤
- 皮肤和结缔组织疾病
- 头颈部鳞状细胞癌
- 食管鳞状细胞癌
- 前列腺肿瘤
- 胃肿瘤
- 结直肠肿瘤
- 卵巢肿瘤
- 癌,非小细胞肺癌
- 宫颈肿瘤
- 黑色素瘤
- 三阴性乳腺肿瘤
- 癌,移行细胞
其他研究编号
- IPH4502-101
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.